Summary
Coronavirus disease 2019 (COVID-19) expresses a wide spectrum of disease severity. We investigated the profile of IgG and IgG subclass antibody responses to SARS– CoV-2 in Tunisian patients with COVID-19 according to disease severity (86 patients with severe disease and 63 with mild to moderate disease). Two in house developed ELISA with excellent performance were used to test for antibodies to the nucleocapsid (N) protein and the receptor-binding domain of the spike antigen (S-RBD) of SARS-CoV-2. IgG, IgG1 and IgG3 antibodies were significantly higher in patients with severe disease compared to non-severe disease. Antibodies to S-RBD or the N protein were dominated by IgG1 and IgG3 or IgG1/IgG3 and IgG2 subclasses respectively. In patients with severe disease, IgG antibodies ‘ appearance to S-RBD was delayed compared to the N protein. IgG subclass imbalance may reflect the pathophysiology of COVID-19 and may herald disease aggravation. This study brings information on the immune responses to SARS-CoV-2 in North African patients and completes the picture drawn on COVID-19 in different African populations and worldwide.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the URGENCE COVID 19 fundraising campaign of Institut Pasteur. This study was also funded by the French Ministry for Europe and Foreign Affairs (MEAE) via the project REPAIR (International Pasteurian research program in response to coronavirus in Africa) coordinated by the Pasteur International Network Association. This work received financial support by the Ministry of Higher Education and Scientific research in Tunisia (PRFCOV19 D5P1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Institut Pasteur de Tunis ethical committee (2020/21/I/LR16IPT/V2).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- ADCC
- Antibody-dependent cellular cytotoxicity
- ADE
- Antibody-dependent enhancement
- AUC
- Area under curve
- COVID-19
- Coronavirus disease 2019
- E. coli:
- Escherichia coli
- ELISA
- Enzyme-Linked Immunosorbent Assay
- HRP
- Horseradish peroxidase
- LB
- Luria Broth
- LIPS
- Luciferase immunoprecipitation system
- MALDI-TOF
- Matrix assisted laser desorption ionization-time of flight
- N
- Nucleocapsid protein
- PBS
- Phosphate buffered saline
- ROC
- Receiver operating curve
- RT-PCR
- Reverse transcription polymerase chain reaction
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- S-RBD
- Receptor-binding domain of the spike protein
